Telix Pharmaceuticals Limited (ASX:TLX)
10.81
-0.19 (-1.73%)
Mar 11, 2026, 3:59 PM AEST
Telix Pharmaceuticals Revenue
In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M USD with 55.61% growth. Telix Pharmaceuticals had revenue of $413.44M in the half year ending December 31, 2025, with 115.29% growth.
Revenue
$803.79M
Revenue Growth
+55.61%
P/S Ratio
3.09
Revenue / Employee
$678.88K
Employees
1,184
Market Cap
3.73B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Jan 1, 2024 | 332.98M | 224.17M | 206.01% |
| Dec 31, 2022 | 108.81M | 103.29M | 1,870.12% |
| Dec 31, 2021 | 5.52M | 1.50M | 37.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mesoblast | 98.02M |
| Clinuvel Pharmaceuticals | 96.30M |
| Neuren Pharmaceuticals | 64.65M |
| PYC Therapeutics | 20.56M |
| Clarity Pharmaceuticals | 10.58M |
| Orthocell | 9.33M |
| Immutep | 7.92M |
| Dimerix | 7.42M |
Telix Pharmaceuticals News
- 18 hours ago - Why Is Telix Pharmaceuticals Stock Gaining Tuesday? - Benzinga
- 1 day ago - Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript - Seeking Alpha
- 1 day ago - ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives - GlobeNewsWire
- 5 days ago - Telix Pharmaceuticals Limited (TLX) Discusses Physician Perspectives on Innovations in PSMA PET CT Imaging for Prostate Cancer Transcript - Seeking Alpha
- 8 days ago - Telix Pharmaceuticals Ltd at TD Cowen Healthcare Conference Transcript - GuruFocus
- 9 days ago - Telix Pharmaceuticals: Scope Of Company Beyond Radio Antibody-Drug Conjugate TLX591-Tx - Seeking Alpha
- 11 days ago - Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging - GlobeNewsWire
- 12 days ago - 1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth - The Motley Fool